


PTO/SB/21 (08-03)


Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		Application Number	09/774,181
		Filing Date	April 26, 2001
		First Named Inventor	Bernhard A. Sabel
		Art Unit	1615
		Examiner Name	Simon J. Oh
Total Number of Pages in This Submission	3	Attorney Docket Number	NPA 101

<b>ENCLOSURES</b> <i>(Check all that apply)</i>		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <b>Statement Under 37 CFR 3.73(b)</b>
<b>Remarks</b> <b>Certificate of Transmission/Mailing is by fax to:</b> (703) 672-9306		

<b>SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT</b>		
Firm or individual name	Patrea L. Pabst, Esq., Reg. No. 31,284 Suite 2000, One Atlantic Center, 1201 West Peachtree Street, N.E., Atlanta, GA 30309-3400	
Signature		
Date	February 6, 2004	

<b>CERTIFICATE OF TRANSMISSION/MAILING</b>		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Patrn Turnbough	
Signature		Date February 6, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

NPA 101 - 092583/00003

Approved for Use through 12/31/2003. MD 0551-00006  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Section of Information: U.S. Patent & Trademark Office, Washington, D.C. 20540-0001

**REVOCATION OF POWER OF  
ATTORNEY WITH  
NEW POWER OF ATTORNEY  
AND  
CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	09/774,181
Filing Date	April 26, 2001
First Named Inventor	Bernhard A. Sabel
Art Unit	1615
Examiner Name	Simon J. Oh
Attorney Docket Number	NPA 101

I hereby revoke all previous powers of attorney given in the above-identified application.

A Power of Attorney is submitted herewith.

10

17. I hereby appoint the practitioners associated with the Customer Number:

23579

Please change the correspondence address for the above-identified application to

The address associated with  
Customer Number:

23678

6

<input type="checkbox"/>	Firm or Individual Name	Patricia L. Pabst, Esq.: Holland & Knight LLP			
Address	One Atlantic Center, Suite 2000				
Address	1201 West Peachtree Street NE				
City	Atlanta	State	Georgia	Zip	30308-3400
Country	US				
Telephone	(404) 817-8473	Fax	(404) 817-8588		

100 98;

Applicant/Inventor:

Assignee of record of the entire interest. See 37 CFR 3.71: Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

**SIGNATURE of Applicant or Assignee of Record**

Name	D. R. Sabel	On behalf of NanoPharm AG
Signature	Z-sabel	
Date	6.02.04	Telephone +49-391-6113-100

NOTE: Signatures of all the members of management of region or the entire system or their representative(s) are required. Signatures multiple items if more than one product is supplied, one by one.

For more information on purchasing this form, call 1-800-PTC-0159 and mention option 2.

NPA 101 - 0758370009

PTO/AS/US (06-03)

Approved for use through 07/01/2008. GMA 965-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

## STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Bernhard A. Sabel, Joerg Kreuter, Svetlana Gelperina, and Ulrike SchroederApplication No./Patent No.: 09/774,181 Filed/Issue Date: April 26, 2001Entitled: Use Of Drug-Loaded Nanoparticles For The Treatment Of Cancers

NanoPharm AG

German corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

Name of Assignee(s)

state that it is:

1.  the assignee of the entire right, title, and interest; or2.  an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_ %

in the patent application/patent identified above by virtue of either:

A.  An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_ or for which a copy thereof is attached.

OR

B.  A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below: Bernhard A. Sabel, Joerg Kreuter, Svetlana Gelperina, and Ulrike Schroeder To: Medinova Medical Consulting GmbH1. From: Medinova Medical Consulting GmbH To: NanoPharm AG  
The document was recorded in the United States Patent and Trademark Office at Reel 012779, Frame 0911, or for which a copy thereof is attached.2. From: Medinova Medical Consulting GmbH To: NanoPharm AG  
The document was recorded in the United States Patent and Trademark Office at Reel 012332, Frame 0579, or for which a copy thereof is attached.3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached. Additional documents in the chain of title are listed on a supplemental sheet. Copies of assignments or other documents in the chain of title are attached.  
(NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 502.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

6.02.04Dr. Bernhard SabelDate  
+49-391-6117-100Typed or printed name  
Dr. B. Sabel

Telephone number

Signature

CEO

Title

This provision of information is required by 37 CFR 3.73(b). The information is required to obtain or make a benefit by the public which is to file (and by the USPTO to process) an application. Consideration is governed by 35 U.S.C. 128 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete. This will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the complete application form to the USPTO. The USPTO will not be liable for any damages resulting from the use of this form. If you require assistance in completing the form, call 1-800-PTO-9199 and select option 7.

MPA 101 - 022382/000097

FEB. 6. 2004 5:20PM HOLLAND & KNIGHT

NO. 9594 P. 1/4

# HOLLAND & KNIGHT LLP

One Atlantic Center  
1201 West Peachtree Street, N.E.  
Suite 2000  
Atlanta, Georgia 30309-3400

404-817-8500  
404-881-0470 FAX

[www.hklaw.com](http://www.hklaw.com)

## FACSIMILE

Annapolis  
Atlanta  
Bethesda  
Boston  
Bradenton  
Chicago  
Fort Lauderdale  
Jacksonville  
Lakeland  
Los Angeles  
Melbourne  
Miami  
New York  
Northern Virginia  
Orlando  
Portland  
Providence  
St. Petersburg  
San Antonio

San Francisco  
Seattle  
Tallahassee  
Tampa  
Washington, D.C.  
West Palm Beach

Holland & Knight LLC

International Offices:  
Caracas\*  
Helsinki  
Mexico City  
Rio de Janeiro  
São Paulo  
Tel Aviv\*  
Tokyo

\*Representative Offices

**OFFICIAL**

**TO:**

Central Processing	U.S. Patent and Trademark Office	(703) 872-9306
NAME	COMPANY/FIRM	FAX NUMBER
Washington	DC	(703) 308-4357
CITY	STATE	(TELEPHONE NUMBER)

FROM: Pam Turnbough for Patrea L. Pabst, Esq.	404-817-8473	4
NAME	TELEPHONE	TOTAL PAGES (Including Cover Sheet)

FOR THE RECORD:		
DATE: February 2004	URGENCY: <input type="checkbox"/> SUPER RUSH	<input checked="" type="checkbox"/> RUSH <input type="checkbox"/> REGULAR
FAXED BY:	FILE #: 092583/00003	CLIENT NAME: NPA 101

CONFIRMED: <input type="checkbox"/> YES <input type="checkbox"/> NO	NAME:	TIME:
If you did not receive all of the pages or find that they are illegible, please call (404) 817-8500		
<b>CONFIDENTIALITY NOTICE:</b> This facsimile, along with any documents, files, or attachments, may contain information that is confidential, privileged, or otherwise exempt from disclosure. If you are not the intended recipient or a person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, printing, distribution or use of any information contained in or attached to this facsimile is strictly prohibited. If you have received this facsimile in error, please immediately notify us by facsimile or by telephone collect at the numbers stated above, and destroy the original facsimile and its attachments without reading, printing, or saving in any manner. Your cooperation is appreciated. Thank you.		

**MESSAGE:**

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Bernhard A. Sabel et al.

Serial No: 09/774,181 Art Unit: 1615

Filed: April 26, 2001 Examiner: Simon J. Oh

For: Use of Drug-Loaded Nanoparticles for the Treatment of Cancers

# 1634884\_v1